2020-2025 Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Report - Production and Consumption Professional Analysis (Impact of COVID-19)

Chronic obstructive pulmonary disease (COPD) is a progressive lung disease which includes emphysema, chronic bronchitis, refractory asthma, and some forms of bronchiectasis. This disease is characterized by increasing breathlessness, wheezing, tightness in chest etc. In the early stages, there may be no symptoms but the symptoms gradually increases in later stages. Shortness of breath, chronic cough, fatigue, frequent flu, weight-loss etc. are the symptoms exhibited in the later stages. Spirometry, chest X-ray, arterial blood gas test etc. are the common tests for diagnosing COPD. Smoking, genetic factors and environmental pollution are some major risk factor that developed chronic obstructive pulmonary diseases.
This report elaborates the market size, market characteristics, and market growth of the Chronic Obstructive Pulmonary Disease (COPD) Drugs industry, and breaks down according to the type, application, and consumption area of Chronic Obstructive Pulmonary Disease (COPD) Drugs. The report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry.

In Chapter 3.4 of the report, the impact of the COVID-19 outbreak on the industry was fully assessed. Fully risk assessment and industry recommendations were made for Chronic Obstructive Pulmonary Disease (COPD) Drugs in a special period. This chapter also compares the markets of Pre COVID-19 and Post COVID-19.
In addition, chapters 8-12 consider the impact of COVID-19 on the regional economy.

Key players in the global Chronic Obstructive Pulmonary Disease (COPD) Drugs market covered in Chapter 13:
Aquinox Pharmaceuticals
MediciNova
Novartis
Invion
Innoviva
Ache Laboratorios Farmaceuticos
Ario Pharma
Orion Corporation
Asmacure
Astellas Pharma
Boehringer Ingelheim
Pharmaxis
Pearl Therapeutics
Mylan
Almirall
Chiesi Farmaceutici
F. Hoffmann-La Roche
Mereo BioPharma
ZAI Lab
BioMarck Pharmaceuticals
Cytokinetics
Palobiofarma
AstraZeneca
Prosonix
Merck
Gilead Sciences

In Chapter 6, on the basis of types, the Chronic Obstructive Pulmonary Disease (COPD) Drugs market from 2015 to 2025 is primarily split into:
Anticholinergic
Oral Corticosteroid
Beta2-agonists
Phosphodiesterase-4 (pde4) Inhibitors
Others

In Chapter 7, on the basis of applications, the Chronic Obstructive Pulmonary Disease (COPD) Drugs market from 2015 to 2025 covers:
Lung Functional Test
Chest x-ray Test
CT Scan
Others

Geographically, the detailed analysis of production, trade of the following countries is covered in Chapter 4.2, 5:
United States
Europe
China
Japan
India

Geographically, the detailed analysis of consumption, revenue, market share and growth rate of the following regions are covered in Chapter 8, 9, 10, 11, 12:
North America (Covered in Chapter 8)
United States
Canada
Mexico
Europe (Covered in Chapter 9)
Germany
UK
France
Italy
Spain
Others
Asia-Pacific (Covered in Chapter 10)
China
Japan
India
South Korea
Southeast Asia
Others
Middle East and Africa (Covered in Chapter 11)
Saudi Arabia
UAE
South Africa
Others
South America (Covered in Chapter 12)
Brazil
Others

Years considered for this report:

Historical Years:

2015-2019

Base Year:

2019

Estimated Year:

2020

Forecast Period:

2020-2025